Open AccessEfficacy of haemodiafiltration treatment with PEPA dialysis membranes in plasma free light chain removal in a patient with primary amyloidosis
Author(s) -
Toshihiko Machiguchi
Publication year - 2002
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/17.9.1689
Subject(s) - medicine , amyloidosis , amyloid (mycology) , nephrotic syndrome , immunoglobulin light chain , hemodialysis , dialysis , cardiac amyloidosis , dialysis therapy , primary systemic amyloidosis , amyloid fibril , heart failure , surgery , disease , pathology , systemic disease , antibody , immunology , amyloid β
Primary amyloidosis is a disease that causes intractable nephrotic syndrome, with continuous progression to end-stage renal failure (ESRF) [1,2]. Furthermore, it causes fatal cardiac conditions such as conduction disturbance and restrictive heart failure [3]. Although regular haemodialysis (HD) therapy has been attempted for ESRF in primary amyloidosis, a successful therapy has not been established yet [1,3]. In this study of a patient with primary amyloidosis, we estimated the removal ratio of free light (L)-chain—a precursor of amyloid fibril—by various blood purification methods. In addition, we examined the usefulness of dimethyl sulfoxide (DMSO).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom